| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Mar 14, 2023
Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced an...
-
Mar 1, 2023
Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that...
-
Jan 4, 2023
Nuvalent, Inc., (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that...
-
Dec 13, 2022Publication provides comprehensive assessment of NVL-520's activity spanning preclinical characterization and preliminary clinical case studies
Publication provides comprehensive assessment of NVL-520's activity spanning preclinical characterization and preliminary clinical case studies CAMBRIDGE, Mass., Dec. 13, 2022 /PRNewswire/ --...
-
Nov 10, 2022Preliminary Phase 1 clinical data from ARROS-1 Study presented at the 2022 EORTC-NCI-AACR Symposium supports best-in-class potential of NVL-520 for patients with ROS1-positive NSCLC
Preliminary Phase 1 clinical data from ARROS-1 Study presented at the 2022 EORTC-NCI-AACR Symposium supports best-in-class potential of NVL-520 for patients with ROS1-positive NSCLC Enrollment...
-
Nov 3, 2022
Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the...
-
Oct 31, 2022
Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the...
-
Oct 31, 2022
Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that it...
-
Oct 28, 2022Favorable preliminary safety profile of NVL-520 suggests potential for a highly ROS1-selective, TRK sparing design, with no dose-limiting toxicities, treatment-related serious adverse events, treatment-related dizziness, or adverse events leading to treatment reductions or discontinuations as of the data cut-off date
Favorable preliminary safety profile of NVL-520 suggests potential for a highly ROS1-selective, TRK sparing design, with no dose-limiting toxicities, treatment-related serious adverse events,...
-
Oct 26, 2022Preclinical data demonstrated that NVL-330 inhibits HER2 exon 20 insertion mutations, is selective for HER2 versus wild-type EGFR, and is brain-penetrant
Preclinical data demonstrated that NVL-330 inhibits HER2 exon 20 insertion mutations, is selective for HER2 versus wild-type EGFR, and is brain-penetrant NVL-655 preclinical data further support...
The information in Nuvalent’s press releases is accurate only as of the date of issuance. Nuvalent assumes no duty to update or revise the information contained in the press releases after their original release date.
